The Comparison of Breast Cancer in Southern China and America: a Multicentre Study in China Versus SEER Database

Yingjie Niu

the Third Affiliated Hospital of Kunming Medical University

Fan Zhang

Affiliated Tumor Hospital of Guangxi Medical University

Dong Chen

the Third Affiliated Hospital of Kunming Medical University

Guolin Ye

First People's Hospital of Foshan

Yong Li

the Third Affiliated Hospital of Kunming Medical University

Yong Zha

the Third Affiliated Hospital of Kunming Medical University

Wenlin Chen

the Third Affiliated Hospital of Kunming Medical University

Dequan Liu

the Third Affiliated Hospital of Kunming Medical University

Xiaoming Liao

Affiliated Tumor Hospital of Guangxi Medical University

Qinghua Huang

Affiliated Tumor Hospital of Guangxi Medical University

Wei Tang

Affiliated Tumor Hospital of Guangxi Medical University

Gengxi Cai

First People's Hospital of Foshan

Rong Guo

the Third Affiliated Hospital of Kunming Medical University

Hongyang Li

the Third Affiliated Hospital of Kunming Medical University

Shicong Tang (✉ tang_shicong@126.com)

the Third Affiliated Hospital of Kunming Medical University

Research Article

Keywords: Breast cancer, tumor pathology, Southern China, SEER database, survival

Posted Date: December 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-940152/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

The comparison of breast cancer in southern China and America: A multicentre study in China versus SEER database

Yingjie Niu^{1,2*}, Fan Zhang^{3*}, Dong Chen^{4*}, Guolin Ye^{5*}, Yong Li¹, Yong Zha¹,
Wenlin Chen², Dequan Liu², Xiaoming Liao³, Qinghua Huang³, Wei Tang³, Gengxi
Cai⁵, Rong Guo^{2#}, Hongyang Li^{1#}, Shicong Tang^{2#}

1. Department of Hepatobiliary and Pancreatic Surgery, the Third Affiliated Hospital
of Kunming Medical University, Yunnan Cancer Hospital, Kunming, Yunnan,
People's Republic of China

2. Department of Breast Surgery, the Third Affiliated Hospital of Kunming Medical
University, Yunnan Cancer Hospital, Kunming, Yunnan, People's Republic of China

3. Department of Breast Surgery, Afiliated Tumor Hospital of Guangxi Medical
University, Nanning, Guangxi, People's Republic of China

4. Department of Ultrasound, Caner Hospital of Yunnan Province, the Third Affiliated
Hospital of Kunming Medical University, Kunming, Yunnan, 650118, China

5. Department of Breast Surgery, The First People's Hospital of Foshan, #81, North
Lingnan Avenue, Chancheng, Foshan, Guangdong, People's Republic of China.

*Contribute equally to this work

#Corresponding author. Rong Guo: guorong2320@126.com

Hongyang Li: 1564356100@qq.com

Abstract: Background and Objective: There are different characteristics of BC in developing countries and developed countries. We intend to study the factors which influence the survival and prognosis of BC between southern China and the United States. **Methods:** To study the two groups BC patients in southern China from 2001 to 2016 and SEER database from 1975 to 2016. To register, collect and analyze the clinicopathological features and treatment information. **Results:** Our study found that there are significant differences in tumor size, positive lymph node status and KI-67 between southern China and SEER cohort ($P<0.000$). **Conclusions:** The age, tumor size, positive-node and KI-67 may cause the difference of morbidity and mortality of BC patients in southern China and SEER cohort.

Keywords: Breast cancer; tumor pathology; Southern China; SEER database; survival

Background

Breast cancer (BC) is one of the most common cancers of women in the world, which is also the second main cause of cancer death in women. There are about 1.5 million women (25% of all cancer women) are diagnosed with BC every year all around the world, and it is estimated to increase to 2.2 million per year by 2025[1-3]. However, there are literatures showed that the mortality of BC in high-income

countries is declining, while it is increasing in low and middle income countries[4].

It is reported that, the incidence of BC in China is expending at twice the rate of the world, which has risen from 23.37/10 million in 2007 to 28.42/10 million in 2013[5, 6]. In addition, there are researches showed that the incidence rate of breast cancer is increasing in China, and it may reach 2 million 500 thousand cases by 2021, however, its survival rate is low, the 5-year survival rate ranged from 40% to 60%^[7, 8]. Furthermore, there are obvious regional differences in the mortality of BC in China. Zhou W et al reported that, the mortality of BC in urban China was higher than that in rural areas, the average annual change of urban women was decrease, while that of rural women was increase[9]. What's more, Wu Z et al found that the participation rate of breast cancer screening among women in Eastern China was higher than that in Western China[10]. Wang X et al suggested that the risk factors of BC in northern and eastern China are associated with body size, especially in premenopausal women[11]. Then, a lot of research suggests that there is a large difference of BC between China and other regions, which may due to the difference of clinicopathological features, the details as follows. Jarzab M et al considered that the prognosis of lumen type G1 tumor is good, while G3 tumor is poor in BC of China[12]. Meanwhile, Zhang X et al reported that, lymph node metastasis seriously affects the prognosis of BC patients. In addition, the expression of Ki-67 and prognosis were closely related to pTNM stage and PR expression[13]. It is indicated that Ki-67 positive can lead to higher histological grade of BC, Wang J et al showed that it is beneficial for Ki-67 expression < 40%, which can significantly increase DFS in BC patients[14]. However,

HER2 overexpression can lead to invasive breast cancer, which overexpression was negatively correlated with the expression of PR and ER. Wang X et al found that the frequency of BRCA1 mutation in triple negative BC patients is higher than that in non-triple negative BC patients in China[15].

In contrast, there are about 12% of women in the United States are diagnosed with BC in their lifetime, nevertheless, it is estimated that there are about 3.1 million BC survivors each year[16, 17]. With the development of treatment strategies, the mortality of BC has been decreased in the United States, which the 5-year survival rate was about 90% after treating[18]. A large number of studies have shown that, BC also has its own characteristics in the United States. DeSantis CE et al reported that BC patients in the United States from 2004 to 2014, young women have higher invasive and specific genomic characteristics, meanwhile, the incidence of HR positive (ER positive or PR positive) breast cancer increased, while the morbidity of HR negative tumors decreased[19].

There are different researchers in the world comparing BC in China and other regions, and finding that there exist some differences between them. Sung H et al suggested that with the widespread assimilation of western lifestyles, the incidence of BC in China is narrowing gradually[20]. Wu AH et al reported that the incidence of BC in Filipino people is significantly higher than that in Japan and China[21]. Zhang G et al found that compared with the white, the expression of TP53 and AKT1 is higher in Chinese, which may be a potential factor affecting the incidence of BC[22]. Yang SY et al found that the morbidity of BC is different between China and other

Asian populations, and the mutation frequency of BRCA2 was much higher than that of BRCA1, by comparison, BRCA1 mutations are more common than BRCA2 mutations in Caucasian populations[23]. Chen L et al researched the Asia and African Americans, discovering that there are more than 50% of BC cases in Asia were lumA subtype, and the basal-like subtype only accounts for 5%, however, in African-American populations, this subtype accounts for more than 30%[24]. Additionally, there are different characteristics of BC in different regions of China. A previous study showed that the incidence of BC is the highest in eastern China, followed by central China, and then in western China[25]. Among these, BRCA1 mutations are more frequent than BRCA2 mutations in patients with familial breast cancer in Henan, central China[26]. Co M et al reported that the age of onset of BC in mainland China is younger than in Hong Kong[27]. Moreover, it has been reported that the incidence of BC in Taiwan, China (similar to that in Hong Kong), is even higher than that in the United States in recent years[28]. However, the comparison of BC patients between southern China and the United States has not been reported. This study aims to investigate the differences of BC patients between southern China and the population-based Surveillance, Epidemiology, and End Results (SEER) cohort.

Researches showed that the age of diagnosis, stage and grade of tumor and treatment methods may be the prognostic factors of BC^[29-31]. Based on these, our study intends to research the age, stage and grade of tumor, ER, PR, HER2, KI-67 and treatment methods, in order to report and analyze the age distribution, clinical characteristics, treatment and prognosis of BC patients in southern China and SEER

database, to compare and analyze the two groups.

Methods

Patients and ethics

Retrospective analysis and compare the patients who have been diagnosed with primary breast cancer in southern China (2001-2016) and SEER database (1975-2016). Overall, there was a total of 525 breast cancer patients were diagnosed in southern China, among them, 15 patients were excluded from this study due to lack of age information. In addition, 129 patients were removed, which without tumor stage, ER, PR, HER2, KI-67 and treatment information. Additionally, there are about 95 patients were lost. Finally, a total of 286 patients were included in the study (Fig. 1). The study was approved by Institutional Review Board of Yunnan Cancer Hospital, Cancer Hospital Affiliated to Guangxi Medical University and Foshan first people's Hospital. Informed consent was obtained from all individual participants included in the study. All procedures implemented in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The SEER cohort was derived from the SEER database (November 2018 submission) by using SEER*Stat software provided by the National Cancer Institute (NCI). There were 65535 breast cancer patients, among them, 26277 cases were lost. Except for without complete information (age, stage and grade of tumor, ER, PR, HER2, KI-67 and treatment) patients, which was about 38662 cases,

there were 596 patients included in this study (Fig. 1).

Figure 1: Flow chart for breast cancer patients in both Southern China and SEER database

Clinical data collection

A retrospective review of medical records and pathology reports was conducted. Staging was performed according to the American Joint Committee on Cancer (AJCC) guidelines[32]. The age of the patients was classified to young adult group (<40), middle aged group (40-70) and aged+ group (>70), and then, calculated the median age of each age group (35, 48, 75), finally, statistical analysis was carried out respectively. A cutoff of 14% for KI-67 was used, which was recommended by 2011 St Gallen consensus panel[33], and then, we divided the group of $KI-67 \geq 14\%$ into two subgroups, according to the median (51.7% in southern China). Patients in southern China were told to have an examination and treatment according to the

guidelines of the breast cancer center and were followed up by telephone, and collect the information about survival and treatment, including date of progression metastasis, date of relapse and date cause of death.

Statistical methods

The IBM SPSS Statistics (Version 21.0; IBM Corp., New York, USA) and GraphPad Prism (Version 6.0; GraphPad software, Inc., LaJolla, CA, USA) were used for statistical analysis. Disease-free survival (DFS) was measured from the beginning of the operation to the first recurrence / metastasis of the tumor or the death of the subject for any reason (the last follow-up time was the patients who lost the follow-up; the patients who were still alive at the end of the study were the end of the follow-up). Overall Survival (OS) was measured from the beginning of operation to death due to any reason. Univariate analysis and multivariate analysis was performed by Cox regression analysis, according to comparing the age (<40 and ≥ 40), tumor size (≤ 2 cm and >2cm), node status, ER, PR, HER2, KI-67, surgery and radiation. Kaplan-Meier method was used to estimate DFS and OS, Log-rank test was used to compare the patients with different clinicopathologic characteristics. The count data were tested by χ^2 test, fisher exact probability method was used when the cases was less than 6. Statistical significance was set at a $P < 0.05$, $P < 0.01$ had significant difference.

Results

Patients

Between 2001 and 2016, a total of 525 females received surgical treatment in the

southern China. Among them, 15 patients without the age information, so excluding this study. There were 51 patients without the information of tumor size, 6 patients without node status, and in the left 453 cases, 75 patients without pathological stage and treatment information and 95 patients were lost, all in all, there were 286 patients included in the southern China cohort. Between 1975 and 2016, a total of 65535 patients were included in SEER database, among them, 26277 patients were lost to follow-up, 35956 patients without the information of lymph node stage, 2678 cases had no tumor size information, 28 patients had no complete information of tumor staging and treatment, so there were about 596 patients were included in the SEER cohort (Fig. 1).

Comparison of clinicopathological features between southern China and SEER cohort

All patients were divided into three subgroups: young adult group (<40), middle aged group (40-70) and aged+ group (>70). Among 510 breast cancer patients in southern China, 101 (19.8%) patients were under 40, what's more, middle aged patients account for the most, about 396 (77.65%) patients. Between 1975 and 2016, there were 65535 BC patients were included SEER database, the proportion of young patients was slightly less than that in southern China, was 4024 (6.14%), but there was no statistical significance between the two ($P=0.923$). However, the middle aged patients account for 41256 (62.95%) in SEER cohort ($P=0.000$). There was a difference between southern China and SEER cohort, the proportion of aged+ group was higher in SEER cohort, which was about 13104 (20.00%), it was significantly

higher than 5 patients (0.98%) in southern China, there was statistically significant ($P=0.048$) (Tab. 1). BC patients in southern China and SEER cohort were compared, the age of newly diagnosed cases in the two groups was 40 to 70 years old. While, there was a different between the two groups: BC patients in the subgroup of 40 to 48 years old (48 years old was the median age of 40-70 years old) were roughly similar to the subgroup of 48 to 70 years old in southern China, there were 194 (38.04%) patients and 202 (39.61%) patients respectively. However, BC patients in SEER cohort were slightly older, it was 9105 (13.89%) patients in the subgroup of 40 to 48 years old, while there were 32151 (49.06%) patients in the subgroup of 48 to 70 years old (Tab. 1).

Tab.1 Clinicopathologic characteristics of breast cancer patients in Southern China and SEER cohorts

Patient characteristics	Southern China	SEER	χ^2 -value	P-value
	N (%)	N (%)		
Age at diagnosis (year)			0.009	0.923
Young adult group (<40)				
<35	38 (7.45)	1495 (2.28)		
≥35	63 (12.35)	2529 (3.86)		
Middle aged group (40-70)			163.919	0.000
≤48	194 (38.04)	9105 (13.89)		
>48	202 (39.61)	32151 (49.06)		
Aged+ group (>70)			0.077	0.048
≤75	8 (1.57)	7151 (10.91)		
>75	5 (0.98)	13104 (20.00)		
Tumor size (cm)			29.923	0.000
Tx	10 (2.01)	51 (0.08)		
Tis	1 (0.20)	1 (0)		
Invasive group				
≤2	79 (15.86)	934 (1.43)		
>2≤5	323 (64.86)	367 (0.56)		
>5	46 (9.24)	63 (0.1)		
Missing	39 (7.83)	64071 (97.8)		
Nodal stage			20387.140	0.000
pN0, no nodal metastasis	206 (40.39)	1145 (1.75)		

pN1, 1–3 nodal metastasis	132 (25.88)	222 (0.34)		
pN2, 4–9 nodal metastasis	76 (14.90)	34 (0.05)		
pN3, ≥ 10 nodal metastasis	49 (9.61)	40 (0.06)		
Unknown	47 (9.22)	64094 (97.80)		
Pathological stage			25.662	0.000
0-1	97 (19.02)	7082 (10.82)		
2	262 (51.37)	14936 (22.81)		
3	133 (26.08)	12993 (19.75)		
4	18 (3.53)	1255 (1.92)		
Unknown	0 (0)	29269 (44.7)		
Estrogen receptor			106.162	0.000
Negative	178 (34.9)	5563 (17.96)		
Positive	290 (56.86)	20233 (65.34)		
Missing	42 (8.24)	5172 (16.70)		
Progesterone receptor			30.794	0.000
Negative	182 (35.69)	8110 (26.2)		
Positive	270 (52.94)	179194 (55.55)		
Missing	58 (11.37)	5646 (18.24)		
HER2-positive			611.595	0.000
Negative	165 (32.35)	1530 (85.62)		
Positive	283 (55.49)	169 (9.46)		
Missing	62 (12.16)	88 (4.92)		

Ki-67 (%)		NA	NA
<14	100 (27.40)	NA (NA)	
<51.7Median	170 (16.58)	NA (NA)	
>=51.7Median	95 (26.03)	NA (NA)	

203

204 According to TNM stage, BC patients were divided into Tx, Tis and invasive
205 group (including $\leq 2\text{cm}$, $2 < 5\text{cm}$, $> 5\text{cm}$), among them, invasive group account for
206 the most, there were 448 (89.96%) patients in southern China and 1364 (2.99%)
207 patients in SEER cohort, $P=0.000$. In southern China, the tumor size was 2 to 5 cm
208 accounted for the most, were 323 (64.86%) patients. However, there were too many
209 data were missing, were 64071 (97.8%) cases, Tis subgroup in the two was both 1
210 case (Tab. 1). There were 257 (50.39%) patients with node metastasis in southern
211 China and 296 (0.45%) cases in SEER cohort. Among the two groups, no lymph node
212 metastasis accounted for the most, were about 206 (40.39%) patients and 1145 (1.75%)
213 patients. While, there were too many data of lymph node status missing, were 29269
214 (44.7%) patients (Tab. 1). Comparing southern China and SEER database, there was
215 statistical significance in tumor stage ($P=0.000$). Among them, the proportion of stage
216 2 was the highest, were 262 (51.37%) cases and 14936 (22.81%) cases respectively.
217 Next, it was stage 3, were 133 (26.08%) cases and 12993 (19.75%) cases. However,
218 there were many missing data about tumor stage in SEER database, were about 29269
219 (44.7%) cases (Tab. 1). The expression of ER was count in both southern China and
220 SEER cohort ($P=0.000$). Among them, ER (+) accounted for a higher proportion,

were 290 (56.86%) cases and 20233 (65.34%) cases respectively, and ER (-) were 178 (34.9%) cases and 5563 (17.96%) cases respectively (Tab. 1). Similarly, the expression of PR in southern China and SEER cohort was also statistically significant ($P=0.000$). Among them, PR (+) was higher in both southern China and SEER cohort, were 270 (52.94%) cases and 179194 (55.55%) cases, PR (-) were 182 (35.69%) cases and 8110 (26.2%) cases (Tab. 1). While, the expression of HER2 was different between the two groups ($P=0.000$). The expression of HER2 (+) accounted for the most in southern China, was 283 (55.49%) cases, but there was only 169 (9.46%) cases in SEER cohort, with the proportion of PR (-) was high, was 1530 (85.62%) cases (Tab. 1). Additionally, the expression of KI-67 was different in the two groups, there were 365 (71.57%) cases of KI-67 (+), among them, it was the most between 14% to 51.7%, was 170 (16.58%) cases. However, there was no data about the expression of KI-67 in SEER cohort (Tab. 1).

Survival and prognosis analysis

Between 2001 and 2016, there were 393 BC patients were followed up in southern China. Meanwhile, between 1975 and 2016, 39258 BC patients with complete follow-up information were analyzed. During the follow-up period, there were 59 patients died, 219 patients were alive and 115 patients relapsed in southern China. While in SEER cohort, there were 3613 patients died and 35645 patients were alive. DFS and OS of all included breast cancer patients were compared: in comparing of DFS, there was no significant different between southern China and SEER cohort ($P=0.133$), but there was significant different in OS ($P=0.000$), and the OS in SEER

cohort was significantly higher than southern China (Fig. 2A-B). Secondly, due to the data of southern China was only included from 2001 to 2016, so layered statistic was used to count the DFS and OS in both southern China and SEER database from 2001 to 2016. Among them, in the first 70 months of follow-up, DFS in southern China was higher than SEER cohort, and then, DFS in SEER cohort was significantly higher than that in southern China ($P=0.035$), and OS in this period also has significant statistical different ($P=0.000$), SEER cohort was significantly higher than that in southern China (Fig. 2C-D). Finally, SEER cohort was analyzed in stages, dividing into 1975 to 2000 and 2001 to 2016 two subgroups, furthermore, DFS and OS of each subgroup were counted respectively. The results showed that, in SEER cohort, the DFS and OS of 2001 to 2016 were significantly higher than 1975 to 2000 ($P=0.000$) (Fig. 2E-F).

Figure 2: Comparison of all patients' DFS and OS in Southern China and SEER database. (A-B) Kaplan-Meier estimates disease-free survival (DFS) and overall survival (OS) of all patients in both Southern China and SEER database, (C-D) Kaplan-Meier estimates DFS and OS of patients in 2001-2016 in both Southern China and SEER database, (E-F) Kaplan-Meier estimates DFS and OS in both 1975-2000 and 2001-2016 in SEER database.

Analyzing and comparing the influence of different clinicopathological features on survival and prognosis of BC patients in southern China. By analyzing the effects of age, tumor size, lymph node status, ER, PR, HER2, KI-67, surgery and radiotherapy on the prognosis of breast cancer, we found that tumor size, positive lymph node status and KI-67 expression affected OS of BC patients in southern China,

267 which had significant statistical different ($P=0.018$, $P=0.000$, $P=0.034$ respectively)
268 (Supplementary Fig. 1). To further analyze and compare the effect of different tumor
269 size on survival of different BC cohorts. There were statistical different of DFS and
270 OS in SEER cohort and southern China when the tumor size (T) $>2\text{cm}$ ($P=0.01$ and
271 $P=0.04$), however, DFS and OS were no statistical different of the two groups when T
272 $\leq 2\text{cm}$ ($P=0.188$ and $P=0.604$) (Fig. 3A-D). Secondly, the effects of different tumor
273 sizes on the survival of BC patients in each cohort were analyzed separately. Among
274 them, tumor size had little effect on DFS in southern China ($P=0.487$), but for OS,
275 there was significant statistical different, OS in T $>2\text{cm}$ group was significantly lower
276 than T $\leq 2\text{cm}$ ($P=0.012$) (Fig. 3E-F). However, for SEER cohort, DFS and OS of
277 T $>2\text{cm}$ group were slightly lower than that of T $\leq 2\text{cm}$ group, but there was no
278 statistical different ($P=0.738$ and $P=0.299$) (Fig. 3G-H). Analyze and compare the
279 effect of different node stage on survival of different BC cohorts. Positive-node
280 affected DFS and OS in both southern China and SEER cohort ($P=0.000$ and
281 $P=0.044$). Meanwhile, negative-node also affected DFS and OS in the two groups
282 ($P=0.000$ and $P=0.000$). OS of SEER cohort with different lymph node status was
283 higher than that of southern China (Fig. 4A-D). Analyzing southern China and SEER
284 cohort separately, DFS and OS of positive-node were lower than negative-node,
285 among them, OS of lymph node status has significant statistical different ($P=0.000$),
286 but DFS of lymph node status has no statistical different ($P=0.448$) (Fig4. E-F). But
287 for SEER cohort, DFS and OS of positive-node was slightly higher than
288 negative-node, while there was no statistical different ($P=0.226$ and $P=0.087$) (Fig4.

G-H). Analyze and compare the effect of expression of KI-67 on survival of southern China. Among the subjects included in this study, DFS and OS of KI-67<14% both higher than $\geq 14\%$, there were significant statistical different ($P=0.05$ and $P=0.034$) (Fig5. A-B). Multivariate analysis and univariate analysis of southern China and SEER cohort was performed by Cox regression analysis. In univariate analysis of DFS, T>2cm, positive-node, ER (+), PR (+), HER2 (+), surgery and radiation all had no statistical different with the increasing risk of death. Among them, the hazard ratio (HR) of KI-67 high expression group was 1.376, 95%CI: 1.000-1.894, $P=0.050$. However, In multivariate analysis of DFS, all the clinicopathological features of the included studies were statistically significant (Tab. 2).

Supplementary figure1: comparison DFS and OS in Southern China under different basic features.

(A-B) Kaplan-Meier estimates DFS and OS of all patients in Southern China, (C-D) Kaplan-Meier estimates DFS and OS of different tumour size in Southern China, (E-F) Kaplan-Meier estimates DFS and OS of different nodal stage in Southern China, (G-H) Kaplan-Meier estimates DFS and OS of different ER stage in Southern China; (I-J) Kaplan-Meier estimates DFS and OS of different PR stage in Southern China, (K-L) Kaplan-Meier estimates DFS and OS of different HER2 stage in Southern China, (M-N) Kaplan-Meier estimates DFS and OS of different KI-67 expression in

Southern China; (O-P) Kaplan-Meier estimates DFS and OS of surgery treatment in Southern
 China; (Q-R) Kaplan-Meier estimates DFS and OS of radiation in Southern China

Figure 3: Comparison of different tumour size in Southern China and SEER database. (A-B)

Kaplan-Meier estimates DFS and OS of patients whose $T>2\text{cm}$ in both Southern China and SEER

database, (C-D) Kaplan-Meier estimates DFS and OS of patients whose $T\leq 2\text{cm}$ in both Southern

China and SEER database, (E-F) Kaplan-Meier estimates DFS and OS of different tumour size in

Southern China, (G-H) Kaplan-Meier estimates DFS and OS of different tumour size in SEER

database.

Figure 4: Comparison of different Nodal stage in Southern China and SEER database. (A-B)

Kaplan-Meier estimates DFS and OS of Node-positive patients in both Southern China and SEER database, (C-D) Kaplan-Meier estimates DFS and OS of Node-negative patients in both Southern China and SEER database, (E-F) Kaplan-Meier estimates DFS and OS of different nodal stage in Southern China, (G-H) Kaplan-Meier estimates DFS and OS of different nodal stage in SEER database.

Figure 5: Comparison of different KI-67 expression in Southern China. (A) Kaplan-Meier estimates DFS of different KI-67 expression in Southern China, (B) Kaplan-Meier estimates OS of different KI-67 expression in Southern China.

Table 2: Cox regression analysis for Disease-free survival in southern China

Variables	Univariate analysis			Multivariate analysis		
	Hazard ratio	95% confidence interval	P-value	Hazard ratio	95% confidence interval	P-value
Age	0.874	0.644-1.186	0.388	0.977	0.600-1.591	0.926
Tumour stage > 2cm	0.894	0.652-1.227	0.488	1.257	0.793-1.990	0.330
Node-positive	1.108	0.850-1.446	0.448	1.116	0.754-1.653	0.584
Estrogen receptor-positive	1.109	0.846-1.454	0.453	1.154	0.660-2.017	0.615
Progesterone receptor-positive	1.116	0.852-1.463	0.426	1.122	0.662-1.904	0.669
HER2-positive	0.885	0.675-1.162	0.380	1.091	0.740-1.608	0.662

Ki-67 high expression	1.376	1.000-1.894	0.050	0.960	0.385-2.392	0.930
Mastectomy	0.934	0.521-1.673	0.818	0.985	0.650-1.492	0.943
Radiation therapy	1.016	0.770-1.342	0.910	0.889	0.596-1.326	0.564

Multivariate analysis and univariate analysis of southern China was performed by Cox regression analysis. In the univariate analysis of OS, it was significantly associated with increased risk of death and T>2cm (HR 3.406, 95%CI: 1.232-9.417, $P=0.018$), positive-node status (HR 0.308, 95%CI: 0.169-0.564, $P=0.000$) and KI-67 high expression (HR 2.128, 95%CI: 1.057-4.285, $P=0.034$). In the multivariate analysis of OS, positive-node status (HR 0.226, 95%CI: 0.098-0.519, $P=0.000$) was significantly associated with increased risk of disease recurrence or death (HR 0.226, 95%CI: 0.098-0.519, $P=0.000$) (Tab. 3).

Tab 3: Cox regression analysis for overall survival in southern China

Variables	Univariate analysis			Multivariate analysis		
	Hazard ratio	95% confidence interval	P-value	Hazard ratio	95% confidence interval	P-value
Age	0.771	0.462-1.288	0.321	0.836	0.386-1.814	0.651
Tumour stage>2cm	3.406	1.232-9.417	0.018	0.710	0.246-2.049	0.526
Node-positive	0.308	0.169-0.564	0.000	0.226	0.098-0.519	0.000
Estrogen receptor-positive	0.716	0.454-1.127	0.149	1.888	0.702-5.079	0.208
Progesterone receptor-positive	0.647	0.404-1.035	0.069	0.561	0.207-1.518	0.255
HER2-positive	0.945	0.599-1.490	0.808	1.576	0.825-3.009	0.168
Ki-67 high expression	2.128	1.057-4.285	0.034	1.013	0.115-8.902	0.990
Mastectomy	3.351	0.463-24.256	0.231	1.020	0.501-2.077	0.957
Radiation therapy	1.088	0.677-1.748	0.727	1.130	0.584-2.188	0.717

Comparison of treatment

346 It had differences of treatments between southern China and SEER cohort (Tab.

Treatment	Southern China	SEER	χ^2 -value	P-value
	N (%)	N (%)		
Chemotherapy			1144.901	0.000
Yes	389 (97.01)	15784 (24.08)		
No	12 (2.99)	49751 (75.92)		
Breast surgery			NA	NA
Breast-conserving surgery	20 (4.91)	11951 (18.24)		
Mastectomy	387 (95.09)			

347 4). There were 389 (97.01%) patients received chemotherapy in southern China, but
348 there were 49751 (75.92%) patients in SEER cohort have not received chemotherapy
349 ($P=0.000$). The treatment of surgery also had a big different, there were 387 (95.09%)
350 patients performed mastectomy (including simple resection and modified radical
351 operation), but for SEER cohort, there were 53584 (81.76%) patients had not
352 performed mastectomy, only 11951 (18.24%) patients had breast surgery (the specific
353 operation method is not clear). However, it was the same of the two about whether to
354 receive radiotherapy or not, and there was a significant statistical different ($P=0.001$).
355 Among them, there were 351 (72.82%) patients had not performed radiotherapy in
356 southern China, with 43107 (65.78%) patients in SEER cohort.

357 **Table 4: Treatment of breast cancer patients in Southern China and SEER cohorts**

358

No breast surgery	0 (0)	53584 (81.76)		
Radiation therapy			10.556	0.001
Yes	131 (27.18)	22428 (34.22)		
No	351 (72.82)	43107 (65.78)		

Changes in morbidity with years

To further analyze and compare the age distribution of BC patients in different years in SEER cohort. Among them, except for 90's, the proportion of BC patients in young adult group (< 40 years old) was gradually increased with time goes by, it were respectively: 70's: 6%, 80's: 6.31%, 90's: 5.76%, 00's: 7.62%, and the median age was 35 year, 36 year, 36 year and 36 year. In all age groups, the incidence of middle-aged group (40-70 years old) was the highest, followed by 63.89%, 61.74%, 62.67% and 66.42%, and the median age was 57 year, 56 year, 56 year and 56 year. In addition, we found that with time going, the morbidity of aged+ group (>70) was decreasing year by year, respectively was 30.11%, 31.95%, 31.57% and 25.96%, and the median age was orderly 78year, 78 year, 78 year and 77 year (Fig. 6).

Figure 6: Comparison of different years all patients' age in SEER database.

Discussion

Our research is a very important one, which firstly analyzed and compared the related factors of survival and prognosis of BC patients in southern China and SEER cohort. What's more, it is the first time to analyze the factors: including age, tumor stage and grade, ER, PR, HER2, KI-67, surgery and radiotherapy, which may influence the survival and prognosis of BC. It is a multi-regional and big data clinical study.

In this study, by comparing and analyzing the age of both southern China and SEER cohort, we found that in southern China from 2001 to 2016, there was about 19.8% BC patients were under 40 year, which was the same as the results of Wang K, who had reported that the incidence of young BC patients in China is about 21.97%^[34]. However, the morbidity of young BC patients in China is significantly higher than that in western countries (about 4-6%)^[35-38], which was similar to the incidence of our study: it was 6.14% of SEER cohort from 1975 to 2016. All of these suggested that the incidence of BC in China is younger than that in western countries, which indicated that age may be a factor affecting the survival and prognosis of BC patients in southern China and the United States.

To further study DFS and OS, we focused on T stage, positive lymph node status, ER, PR, HER2, KI-67 expression of BC patients, and thought that T stage, positive lymph node status and KI-67 expression all could be regarded as factors, which affected the survival and prognosis of BC patients. Other scholars had also studied tumor stage, and found that there were about 60% to 70% of BC patients were

396 diagnosed with stage 1, which was higher than Asian countries, but there were only
397 about 10% women were stage 4[39]. This research was similar as our results, our
398 finding showed that most BC patients in southern China from 2001 to 2016 could be
399 diagnosed at early time, among them, there were about 64.86% of patients with T2
400 BC, 40.39% of patients with N0, 51.37% of patients with stage 2. However, the early
401 diagnosis rate of BC in China is far lower than that in the United States. It showed
402 that in SEER cohort, there were about 65.96% of patients with T1, 79.46% of patients
403 with N0 and 41.18% of patients with stage 2. Cox regression analysis showed that T
404 stage and positive lymph node status were important factors affecting OS of BC.
405 Therefore, we further to prove that stages and grades of tumor had a significant
406 impact on the survival and prognosis of BC. Meanwhile, China should to further
407 strengthen the early diagnosis and treatment of BC, so as to improve the prognosis of
408 BC patients in China.

409 Besides, we further to explore the effect of ER, PR, HER2, KI-67 expression on
410 survival and prognosis of BC. The proportion of ER (+) BC patients was similar in
411 both southern China and SEER cohort. It was 56.86% in southern China and 65.34%
412 in SEER cohort, which was slightly lower than that had been reported (about 70%)^[40].
413 It may be related to excessive data deletion in SEER cohort, which was about 16.7%
414 of ER data were missing in this study. There were studies have showed that the most
415 important factors affecting the prognosis of BC were tumor grade and ER status^[41].
416 However, in our study, ER was not an indicator of survival and prognosis of BC.
417 Additionally, there were different treatment methods of BC according to the different

status of hormone receptor (HR). Endocrine therapy could be used for ER or PR positive patients, but the effect of chemotherapy was not as good as these of negative patients, and the different treatment methods could significantly affect the prognosis of BC. Therefore, PR was also an important factor affecting the prognosis of BC. In our study, there was 52.94% of PR positive in southern China, and 55.55% of that in SEER cohort, there was significant statistical different between the two groups ($P=0.000$). Similarly, the results of Cox regression analysis showed that PR was also not an indicator of survival and prognosis of BC, which may had a relationship between a large data missing. In addition, Ding L et al found that BC with HER2 and KI-67 overexpression had higher lymph node metastasis rate and higher AJCC tumor stage^[42, 43], which was the same as our researches. In this study, HER2 positive were 55.49% and 9.46% in southern China and SEER cohort respectively ($P=0.000$), which was consistent with the literature that BC cells from young patients are more likely to show HER2 positive expression^[34]. Besides, KI-67 positive was 70.01% in southern China, which high expression was also an important factor affecting OS in BC patients. However, DFS was detected by χ^2 test when KI-67 was regarded as an independent factor, $P=0.05$, but we thought that this was mainly due to the small sample size, the trend in the conclusion was still valid, with the sample size continues to increase, the value of P may gradually decrease. In summary, our results showed that T stage, positive-node status, KI-67 expression were all important factors affecting the prognosis of BC, which also reflected that BC patients in southern China and the United States have different biological behaviors and pathogenesis.

Additionally, the treatment methods of BC were also important factors affecting its prognosis. At present, the main treatments of BC were surgery, radiotherapy, chemotherapy, targeted therapy and hormone therapy^[44, 45]. Among them, surgery can significantly reduce the mortality rate, which is the most critical step in the treatment of breast cancer, there are five common surgical methods: Breast conserving surgery (BCS), simple mastectomy (SM), modified radical mastectomy (MRM), radical mastectomy (RM) and extensive radical mastectomy (ERM)^[46]. Among them, Bartelink H et al reported that BCS has the equivalence with mastectomy^[47]. However, the comparison of treatment methods between southern China and the United States has not yet reported, we had studied this for the first time. In this study, BC patients enrolled in the study in southern China all underwent surgery, and the treatment including BCS and mastectomy (including SM and MRM). Among them, there were about 95.09% of BC patients performed mastectomy and 4.91% of that performed BCS, and the implementation rate of BCS was significantly lower than that of developed countries, which was similar to the results of Gupta A: the highest implementation rate of BCS in China is only 8.6%^[48]. However, there were only 18.24% of BC patients performed mastectomy in SEER cohort, 81.76% of that had not. While, there was no significant effects on DFS and OS for whether performing surgery, which suggesting that surgery had little effect on the survival and prognosis of BC. But for SEER cohort had not include the details of surgical procedures, so its' effects on survival and prognosis of BC were not studied and analyzed, which may be a potential factor. In recent years, a number of large randomized trials have shown that

radiotherapy could significantly reduce the local recurrence of BC, so as to improve the breast preservation rate and obtain good survival rate[48]. However, in this study, the radiotherapy rate of BC patients in southern China and SEER cohort were both not high, were 27.18% and 34.22% respectively, and there were significant statistical different between the two ($P=0.001$). Nevertheless, the results of Cox regression analysis showed that radiotherapy had no significant effect on both DFS and OS, which may be related to a low radiotherapy rate, but it should be further studied and analyzed. Besides, chemotherapy was also an important treatment for BC, we found that most of BC patients in southern China are treated with chemotherapy, which was approximately 97.01%. But there were only about 24.08% of BC patients had received chemotherapy in SEER cohort ($P=0.000$), which indicated that there are great differences in BC treatment between China and the United States.

Additionally, as time goes by (from 70's to 90's), the proportion of young BC patients in SEER cohort increased gradually, while the proportion of elderly patients decreased gradually. What's more, the median age of diagnosis was gradually constant, it were 36 year, 56 year and 77 year respectively, which may be related to the early diagnosis of BC.

There are some limitations to this study. The data from southern China cohort are from Yunnan Cancer Hospital, Afiliated Tumor Hospital of Guangxi Medical University and The First People's Hospital of Foshan, these data may therefore be slightly different from that of the National Cancer Registry System. In addition, the presence of missing data and limited follow-up time can be considered weaknesses of

this study. Other limitations include the lack of data on surgical procedures, KI -67 statuses and endocrine therapy in SEER cohort, which limited the analysis of their influence on patients' survival improvements.

Conclusion

In conclusion, our study suggested that T stage, positive lymph node status and KI-67 expression rate were important factors affecting the prognosis of BC, and played an important role in the development process of BC.

Acknowledgements

Not applicable.

Authors' contributions

SCT designed the study, FZ collected and interpreted the data, YJN and SCT carried out the statistical analysis, RG, HYL and DQL provided administrative support, YJN, DC, and WLC provision of study materials or patients. All authors read and approved the final manuscript.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81960542, 81960517, 81660437, 81760478); Scientific Research Foundation of Yunnan Education Department (grant no. 2019J1288 and 2020J0198)

and Joint project of Kunming Medical University (2018FE001(-068)).

Availability of data and materials

The raw data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.

Ethics approval and consent to participate

All procedures implemented in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethics/Institutional Review Board approval of research—Yunnan Cancer Hospital, Cancer Hospital Affiliated to Guangxi Medical University and Foshan first people's Hospital. Informed consent was obtained from all individual participants included in the study.

Consent for publication

All patients enrolled in the study signed the consent for publication.

Conflict of interests

The authors have no conflicts of interest to declare.

References

- 528 1. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP,
529 Zhu HP: **Risk Factors and Preventions of Breast Cancer.** *Int J Biol Sci*
530 2017, **13**:1387-1397.
- 531 2. Cha YJ, Kim ES, Koo JS: **Amino Acid Transporters and Glutamine**
532 **Metabolism in Breast Cancer.** *Int J Mol Sci* 2018, **19**.
- 533 3. Zujewski JA, Dvaladze AL, Ilbawi A, Anderson BO, Luciani S, Stevens L,
534 Torode J: **Knowledge Summaries for Comprehensive Breast Cancer**
535 **Control.** *J Glob Oncol* 2018, **4**:1-7.
- 536 4. Melisko ME, Gradishar WJ, Moy B: **Issues in Breast Cancer Survivorship:**
537 **Optimal Care, Bone Health, and Lifestyle Modifications.** *Am Soc Clin*
538 *Oncol Educ Book* 2016, **35**:e22-29.
- 539 5. Sun L, Legood R, Sadique Z, Dos-Santos-Silva I, Yang L: **Cost-effectiveness**
540 **of risk-based breast cancer screening programme, China.** *Bull World*
541 *Health Organ* 2018, **96**:568-577.
- 542 6. Yuan X, Yi F, Hou C, Lee H, Zhong X, Tao P, Li H, Xu Z, Li J: **Induced**
543 **Abortion, Birth Control Methods, and Breast Cancer Risk: A**
544 **Case-Control Study in China.** *J Epidemiol* 2019, **29**:173-179.
- 545 7. Lou Z, Fei X, Christakos G, Yan J, Wu J: **Improving Spatiotemporal Breast**
546 **Cancer Assessment and Prediction in Hangzhou City, China.** *Sci Rep* 2017,
547 **7**:3188.
- 548 8. Peng Z, Wei J, Lu X, Zheng H, Zhong X, Gao W, Chen Y, Jing J: **Treatment**
549 **and survival patterns of Chinese patients diagnosed with breast cancer**
550 **between 2005 and 2009 in Southwest China: An observational,**
551 **population-based cohort study.** *Medicine (Baltimore)* 2016, **95**:e3865.
- 552 9. Zhou W, Zhang Z, Bi Y, Wang L, Liu X, Yu C: **[Joinpoint regression**
553 **analysis for the mortality trend of breast cancer in Chinese female from**
554 **1987 to 2014].** *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2018, **43**:210-215.
- 555 10. Wu Z, Liu Y, Li X, Song B, Ni C, Lin F: **Factors associated with breast**
556 **cancer screening participation among women in mainland China: a**
557 **systematic review.** *BMJ Open* 2019, **9**:e028705.
- 558 11. Wang X, Li L, Gao J, Liu J, Guo M, Liu L, Wang W, Wang J, Xing Z, Yu Z,
559 Wang X: **The Association Between Body Size and Breast Cancer in Han**
560 **Women in Northern and Eastern China.** *Oncologist* 2016, **21**:1362-1368.
- 561 12. Jarzab M, Stobiecka E, Badora-Rybicka A, Chmielik E, Kowalska M, Bal W,
562 Polakiewicz-Gilowska A, Bobek-Billewicz B, Lange D, Tarnawski R:
563 **Association of breast cancer grade with response to neoadjuvant**
564 **chemotherapy assessed postoperatively.** *Pol J Pathol* 2019, **70**:91-99.
- 565 13. Zhang X, Tang B, Zou D, Yang H, Qiao E, He X, Yu F: **Discussion of**
566 **relationships among changes of pathological indicators, postoperative**
567 **lymphedema of the upper limb, and prognosis of patients with breast**
568 **cancer.** *Biosci Rep* 2019, **39**.
- 569 14. Wang J, Sang D, Xu B, Yuan P, Ma F, Luo Y, Li Q, Zhang P, Cai R, Fan Y, et
570 al: **Value of Breast Cancer Molecular Subtypes and Ki67 Expression for**

the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. *Medicine (Baltimore)* 2016, **95**:e3518.

15. Wang X, Liu H, Maimaitiaili A, Zhao G, Li S, Lv Z, Wu D, Shi A, Guan X, Jia H, et al: **Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.** *Mol Genet Genomic Med* 2019, **7**:e677.
16. Song JL, Chen C, Yuan JP, Sun SR: **Progress in the clinical detection of heterogeneity in breast cancer.** *Cancer Med* 2016, **5**:3475-3488.
17. Tesarova P: **Specific Aspects of Breast Cancer Therapy of Elderly Women.** *Biomed Res Int* 2016, **2016**:1381695.
18. Barrios CH, Reinert T, Werutsky G: **Global Breast Cancer Research: Moving Forward.** *Am Soc Clin Oncol Educ Book* 2018, **38**:441-450.
19. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A: **Breast cancer statistics, 2017, racial disparity in mortality by state.** *CA Cancer J Clin* 2017, **67**:439-448.
20. Sung H, Rosenberg PS, Chen WQ, Hartman M, Lim WY, Chia KS, Wai-Kong Mang O, Tse L, Anderson WF, Yang XR: **The impact of breast cancer-specific birth cohort effects among younger and older Chinese populations.** *Int J Cancer* 2016, **139**:527-534.
21. Wu AH, Vigen C, Lee E, Tseng CC, Butler LM: **Traditional Breast Cancer Risk Factors in Filipina Americans Compared with Chinese and Japanese Americans in Los Angeles County.** *Cancer Epidemiol Biomarkers Prev* 2016, **25**:1572-1586.
22. Zhang G, Wang Y, Chen B, Guo L, Cao L, Ren C, Wen L, Li K, Jia M, Li C, et al: **Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.** *Ann Transl Med* 2019, **7**:179.
23. Yang SY, Aisimutula D, Li HF, Hu Y, Du X, Li J, Luan MX: **Mutational analysis of BRCA1/2 gene and pathologic characteristics from Kazakh population with sporadic breast cancer in northwestern China.** *Genet Mol Res* 2015, **14**:13151-13161.
24. Chen L, Zeng T, Pan X, Zhang YH, Huang T, Cai YD: **Identifying Methylation Pattern and Genes Associated with Breast Cancer Subtypes.** *Int J Mol Sci* 2019, **20**.
25. Cheng Y, Yan Y, Gong J, Yang N, Nie S: **Trends in incidence and mortality of female breast cancer during transition in Central China.** *Cancer Manag Res* 2018, **10**:6247-6255.
26. Wang L, Zhou S, Xie J, Gao H, Wang F, Zhou J, Wang Y, Wang H: **BRCA1 germline mutations dominate familial breast cancer patients in Henan China.** *J Thorac Dis* 2017, **9**:5295-5299.
27. Co M, Kwong A: **Young onset breast cancer in Southern China - a 5-year clinico-pathological study from a multi-centre database.** *Cancer Treat Res Commun* 2020, **24**:100182.

- 614 28. Wang F, Dai J, Li M, Chan WC, Kwok CC, Leung SL, Wu C, Li W, Yu WC,
615 Tsang KH, et al: **Risk assessment model for invasive breast cancer in Hong**
616 **Kong women.** *Medicine (Baltimore)* 2016, **95**:e4515.
- 617 29. Hortobagyi GN, Edge SB, Giuliano A: **New and Important Changes in the**
618 **TNM Staging System for Breast Cancer.** *Am Soc Clin Oncol Educ Book*
619 2018, **38**:457-467.
- 620 30. Nahleh Z, Otoukesh S, Mirshahidi HR, Nguyen AL, Nagaraj G, Botrus G,
621 Badri N, Diab N, Alvarado A, Sanchez LA, Dwivedi AK: **Disparities in**
622 **breast cancer: a multi-institutional comparative analysis focusing on**
623 **American Hispanics.** *Cancer Med* 2018, **7**:2710-2717.
- 624 31. Unlu O, Kiyak D, Caka C, Yagmur M, Yavas HG, Erdogan F, Sener N, Oguz
625 B, Babacan T, Altundag K: **Risk factors and histopathological features of**
626 **breast cancer among women with different menopausal status and age at**
627 **diagnosis.** *J BUON* 2017, **22**:184-191.
- 628 32. Holm J, Humphreys K, Li J, Ploner A, Cheddad A, Eriksson M, Tornberg S,
629 Hall P, Czene K: **Risk factors and tumor characteristics of interval cancers**
630 **by mammographic density.** *J Clin Oncol* 2015, **33**:1030-1037.
- 631 33. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ,
632 Panel m: **Strategies for subtypes--dealing with the diversity of breast**
633 **cancer: highlights of the St. Gallen International Expert Consensus on the**
634 **Primary Therapy of Early Breast Cancer 2011.** *Ann Oncol* 2011,
635 **22**:1736-1747.
- 636 34. Wang K, Ren Y, Li H, Zheng K, Jiang J, Zou T, Ma B, Li H, Liu Q, Ou J, et al:
637 **Comparison of Clinicopathological Features and Treatments between**
638 **Young (≤ 40 Years) and Older (> 40 Years) Female Breast Cancer**
639 **Patients in West China: A Retrospective, Epidemiological, Multicenter,**
640 **Case Only Study.** *PLoS One* 2016, **11**:e0152312.
- 641 35. Feng F, Wei Y, Zheng K, Li Y, Zhang L, Wang T, Zhang Y, Li H, Ren G, Li
642 F: **Comparison of epidemiological features, clinicopathological features,**
643 **and treatments between premenopausal and postmenopausal female**
644 **breast cancer patients in western China: a retrospective multicenter study**
645 **of 15,389 female patients.** *Cancer Med* 2018, **7**:2753-2763.
- 646 36. Huang Z, Wen W, Zheng Y, Gao YT, Wu C, Bao P, Wang C, Gu K, Peng P,
647 Gong Y, et al: **Breast cancer incidence and mortality: trends over 40 years**
648 **among women in Shanghai, China.** *Ann Oncol* 2016, **27**:1129-1134.
- 649 37. Ye DM, Li Q, Yu T, Wang HT, Luo YH, Li WQ: **Clinical and epidemiologic**
650 **factors associated with breast cancer and its subtypes among Northeast**
651 **Chinese women.** *Cancer Med* 2019, **8**:7431-7445.
- 652 38. Radecka B, Litwiniuk M: **Breast cancer in young women.** *Ginekol Pol* 2016,
653 **87**:659-663.
- 654 39. Bhattacharyya GS, Doval DC, Desai CJ, Chaturvedi H, Sharma S,
655 Somashekhar SP: **Overview of Breast Cancer and Implications of**
656 **Overtreatment of Early-Stage Breast Cancer: An Indian Perspective.** *JCO*
657 *Glob Oncol* 2020, **6**:789-798.

- 658 40. Martei YM, Pace LE, Brock JE, Shulman LN: **Breast Cancer in Low- and**
659 **Middle-Income Countries: Why We Need Pathology Capability to Solve**
660 **This Challenge.** *Clin Lab Med* 2018, **38**:161-173.
- 661 41. Tian Z, Tang J, Yang Q, Li X, Zhu J, Wu G: **Atypical ubiquitin-binding**
662 **protein SHARPIN promotes breast cancer progression.** *Biomed*
663 *Pharmacother* 2019, **119**:109414.
- 664 42. Zhang L, Huang Y, Feng Z, Wang X, Li H, Song F, Liu L, Li J, Zheng H,
665 Wang P, et al: **Comparison of breast cancer risk factors among molecular**
666 **subtypes: A case-only study.** *Cancer Med* 2019, **8**:1882-1892.
- 667 43. Ding L, Zhang Z, Xu Y, Zhang Y: **Comparative study of Her-2, p53, Ki-67**
668 **expression and clinicopathological characteristics of breast cancer in a**
669 **cohort of northern China female patients.** *Bioengineered* 2017, **8**:383-392.
- 670 44. Fisusi FA, Akala EO: **Drug Combinations in Breast Cancer Therapy.**
671 *Pharm Nanotechnol* 2019, **7**:3-23.
- 672 45. Zhang M, Sun H, Zhao S, Wang Y, Pu H, Wang Y, Zhang Q: **Expression of**
673 **PD-L1 and prognosis in breast cancer: a meta-analysis.** *Oncotarget* 2017,
674 **8**:31347-31354.
- 675 46. Bao X, Sun K, Tian X, Yin Q, Jin M, Yu N, Jiang H, Zhang J, Hu Y: **Present**
676 **and changing trends in surgical modalities and neoadjuvant**
677 **chemotherapy administration for female breast cancer in Beijing, China:**
678 **A 10-year (2006-2015) retrospective hospitalization summary**
679 **report-based study.** *Thorac Cancer* 2018, **9**:707-717.
- 680 47. Bartelink H: **The changing landscape in radiotherapy for breast cancer:**
681 **Lessons from long term follow-up in some European breast cancer trials.**
682 *Radiother Oncol* 2016, **121**:348-356.
- 683 48. Gupta A, Ohri N, Haffty BG: **Hypofractionated radiation treatment in the**
684 **management of breast cancer.** *Expert Rev Anticancer Ther* 2018,
685 **18**:793-803.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryfigure1.tiff](#)